Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Platelet-derived LAP supports progression of osteolytic bone metastases in mice
March 3rd, 2005
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer, according to a study from France. "The role of lysophosphatidic acid (LPA) in cancer is poorly understood. Here we provide evidence for a role of LPA in the progression of breast cancer bone metastases," wrote A. Boucharaba and colleagues, University of Lyon 1, in the Journal of Clinical Investigation. "LPA receptors LPA(1), LPA(2), and LPA(3) were expressed in human primary breast tumors and a series of human breast cancer cell lines. The inducible overexpression of LPA in MDA-BO2 breast cancer cells specifically sensitized these...
Source: Women's Health Weekly (2005-03-03)
|
